3 days ago · About Vanda Pharmaceuticals, Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to …

1 day ago · Vanda will pay AnaptysBio $10m upfront along with a $5m payment for the current drug supply. Anaptys will receive future regulatory approval and sales milestones amounting to …

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

2 days ago · Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the …

1 day ago · Vanda will pay AnaptysBio a total $15 million: $10 million upfront and another $5 million for its existing supply of the drug. Vanda would also be on the hook for up to $35 million …

2 days ago · Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply Anaptys to receive a 10% royalty on global net …

3 days ago · Vanda Pharmaceuticals and AnaptysBio announced today that an exclusive, global license agreement has been reached to develop imsidolimab for the treatment of generalized …

2 days ago · Vanda Pharmaceuticals Contact: ... AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing …

2 days ago · AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two …

3 days ago · Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab, which has successfully …